The new report by Expert Market Research titled, ‘Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Analysis, Report and Forecast 2021-2026’, gives an in-depth analysis of the global acute bacterial skin and skin structure infections (ABSSSI) treatment market, assessing the market based on its segments like infection type, route of administration, distribution channels and regions.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.
Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-market/requestsample
The key highlights of the report include:
Market Overview (2016-2026)
- Forecast CAGR (2021-2026): 7%
- Forecast Market Size (2026): USD 14 Billion
In the historical period (2016-2020), the number of cases of ABSSS infections due to Methicillin-Rresistant Staphylococcus Aaureus (MRSA) has been rising, which has also subsequently increased the demand for ABSSSI treatments. The factors driving these have been the newer variants of infectious bacteria as well as the same bacteria evolving to become resistant to antibiotics.
The same factors are expected to work as driving forces for the industry to push the demand for ABSSSI treatments. Additionally, a rise in demand from Asia Pacific is also expected to increase at a healthy growth ratethe CAGR.
Industry Definition and Major Segments
ABSSS infections are infections caused by bacterial pathogens like streptococcus pyogenes and Staphylococcus aureus, in the form of carbuncles, post-surgery wound infections and traumatic wound infections. These may be treated according to the infecting pathogen using antibiotics or surgical procedures.
The highest market share is found in North America, while the highest CAGR may be found in the Asia Pacific region in the forecast period 2021-2026, because of rapidly growing populations, growing awareness and increasing medical infrastructure in the country.
The market can be segmented based on infection type into:
- Hospital-Aacquired ABSSSI
- Community-Aacquired ABSSSI
Different routes of administration may be used for these treatments as follows:
The industry may be differentiated on the basis of distribution channel:
- Hospital Pharmacy
- Retail Pharmacy
On the basis of regional markets, the industry is divided into:
1 North America
1.1 United States of America
2.2 United Kingdom
3 Asia Pacific
4 Latin America
5 Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.4 South Africa
Since the pathogens involved in these infections undergo evolution to form resistant strains, it is necessary for companies involved in pharmaceutical R&D to roll out newer drugs which can treat these new variants. Furthermore, the efficacy and the side-effects involved with the drugs may also be reduced because of such R&D activities. It is expected that these improved drugs may help the demand for these treatments to rise greatly.
Key Market Players
The major players in the market are Debiopharm International SA, Melinta Therapeutics, Inc., Paratek Pharmaceuticals, Inc., and GlaxoSmithKline PLC, amongst others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.